Akorn Reaches New 52-Week High (AKRX)
NEW YORK (
) --
(Nasdaq:
) hit a new 52-week high Wednesday as it is currently trading at $11.85, above its previous 52-week high of $11.77 with 324,300 shares traded as of 10:10 a.m. ET. Average volume has been 1.3 million shares over the past 30 days.
Akorn has a market cap of $1.07 billion and is part of the
sector and
industry. Shares are down 0.4% year to date as of the close of trading on Tuesday.
Akorn, Inc. engages in the manufacture and marketing of diagnostic and therapeutic pharmaceutical products, hospital drugs, and injectable pharmaceuticals in the United States and internationally. The company has a P/E ratio of 18.5, below the average drugs industry P/E ratio of 18.7 and above the S&P 500 P/E ratio of 17.7.
- Sign up for TheStreet's FREE Dividend and Income Investor Newsletter
TheStreet Ratings rates Akorn as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. You can view the full
.
See all
52-week high stocks
or get investment ideas from our
.
null
